FR22C1030I1 - Formes cristallines d'un inhibiteur de la prolyle hydroxylase - Google Patents

Formes cristallines d'un inhibiteur de la prolyle hydroxylase

Info

Publication number
FR22C1030I1
FR22C1030I1 FR22C1030C FR22C1030C FR22C1030I1 FR 22C1030 I1 FR22C1030 I1 FR 22C1030I1 FR 22C1030 C FR22C1030 C FR 22C1030C FR 22C1030 C FR22C1030 C FR 22C1030C FR 22C1030 I1 FR22C1030 I1 FR 22C1030I1
Authority
FR
France
Prior art keywords
crystalline forms
prolyl hydroxylase
hydroxylase inhibitor
inhibitor
prolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1030C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1030(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of FR22C1030I1 publication Critical patent/FR22C1030I1/fr
Application granted granted Critical
Publication of FR22C1030I2 publication Critical patent/FR22C1030I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
FR22C1030C 2012-07-16 2022-06-15 Formes cristallines d'un inhibiteur de la prolyle hydroxylase Active FR22C1030I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US201361768297P 2013-02-22 2013-02-22
US201361832566P 2013-06-07 2013-06-07
PCT/US2013/050539 WO2014014835A2 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor
EP13740185.7A EP2872488B1 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor

Publications (2)

Publication Number Publication Date
FR22C1030I1 true FR22C1030I1 (fr) 2022-09-09
FR22C1030I2 FR22C1030I2 (fr) 2024-08-02

Family

ID=48857025

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1030C Active FR22C1030I2 (fr) 2012-07-16 2022-06-15 Formes cristallines d'un inhibiteur de la prolyle hydroxylase

Country Status (28)

Country Link
US (5) US9115085B2 (ja)
EP (3) EP3470397B1 (ja)
JP (2) JP6491093B2 (ja)
KR (4) KR102149380B1 (ja)
CN (9) CN107501177B (ja)
AU (1) AU2013290438C1 (ja)
BR (1) BR112015001101A2 (ja)
CA (1) CA2879242C (ja)
CY (2) CY1120805T1 (ja)
DK (2) DK3470397T3 (ja)
ES (2) ES2689430T3 (ja)
FR (1) FR22C1030I2 (ja)
HK (1) HK1243409A1 (ja)
HR (2) HRP20220182T1 (ja)
HU (2) HUE057925T2 (ja)
IL (1) IL236626B (ja)
IN (1) IN2015KN00262A (ja)
LT (3) LT3470397T (ja)
MX (1) MX355428B (ja)
MY (1) MY182428A (ja)
NO (1) NO2022024I1 (ja)
NZ (1) NZ704662A (ja)
PL (2) PL3470397T3 (ja)
PT (2) PT2872488T (ja)
RS (2) RS63122B1 (ja)
SG (3) SG10202111314YA (ja)
SI (2) SI2872488T1 (ja)
WO (1) WO2014014835A2 (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1644336T1 (sl) 2003-06-06 2011-06-30 Fibrogen Inc Heteroarilne spojine, ki vsebujejo duĺ ik in njihova uporaba pri zviĺ anju endogenega eritropoetina
EP2370422B1 (en) 2008-11-14 2019-06-05 Fibrogen, Inc. Thiochromene derivatives as hif hydroxylase inhibitors
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
IN2015KN00265A (ja) 2012-07-16 2015-06-12 Fibrogen Inc
CN107501177B (zh) * 2012-07-16 2018-12-07 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106916105A (zh) * 2015-12-28 2017-07-04 徐州万邦金桥制药有限公司 一种纯化可博美的方法
US11510917B2 (en) 2016-02-19 2022-11-29 Cornell University HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN108017583B (zh) * 2016-11-01 2021-04-06 徐州万邦金桥制药有限公司 一种可博美的制备方法
CN107382986B (zh) * 2017-08-02 2022-09-20 江苏艾立康医药科技有限公司 4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途
WO2019030711A1 (en) * 2017-08-11 2019-02-14 Dr. Reddy’S Laboratories Limited POLYMORPHS AND CO-CRYSTALS OF ROXADUSTAT
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
SI3679017T1 (sl) 2017-09-04 2022-01-31 Sandoz Ag Kokristal oralno razpoložljivega zaviralca HIF prolil hidroksilaze
CN112166105B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚(亚砜)取代苯类化合物及其用途
CN111320583A (zh) * 2018-12-14 2020-06-23 广东东阳光药业有限公司 诺德司他新晶型及其制备方法
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法
WO2020217190A1 (en) * 2019-04-26 2020-10-29 Dr. Reddy’S Laboratories Limited Process for the purification of roxadustat
CN112679428A (zh) * 2019-10-17 2021-04-20 罗欣药业(上海)有限公司 罗沙司他新晶型及其制备方法
KR20220088743A (ko) * 2019-10-22 2022-06-28 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 저산소 유발 인자-프롤릴 하이드록실라제 억제제의 결정 형태
CN110721185B (zh) * 2019-11-13 2022-04-12 南京市儿童医院 罗沙司他用于心肌保护的用途
CN112961107B (zh) * 2019-12-13 2024-06-25 罗欣药业(上海)有限公司 罗沙司他的晶型及其制备方法
TW202207930A (zh) * 2020-03-17 2022-03-01 印度商卡地拉保健有限公司 包含ｈｉｆ脯胺醯基羥化酶抑制劑之調和物
CN111205224B (zh) * 2020-04-22 2020-08-25 南京佰麦生物技术有限公司 一种罗沙司他水合物的晶型及其制备方法和应用
CN113754569B (zh) * 2020-06-04 2024-07-02 四川国为制药有限公司 一种中间体化合物及其制备方法和用途
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN114057643B (zh) * 2020-08-04 2023-02-28 成都苑东生物制药股份有限公司 一种罗沙司他共晶及其制备方法
CN112500344B (zh) * 2020-11-18 2022-07-01 江苏豪森药业集团有限公司 罗沙司他晶型及其制备方法
CN112194624A (zh) * 2020-11-18 2021-01-08 江苏豪森药业集团有限公司 一种异喹啉类化合物的晶型及其制备方法
CN115724796A (zh) * 2021-08-26 2023-03-03 成都苑东生物制药股份有限公司 一种罗沙司他新晶型及其制备方法
CN113956200A (zh) * 2021-12-16 2022-01-21 南京威凯尔生物医药科技有限公司 一种粒径控制的罗沙司他原料药的结晶工艺

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
US6130231A (en) 1996-11-27 2000-10-10 Dupont Pharmaceuticals Integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1315220B1 (it) * 1999-12-13 2003-02-03 Ipm Ind Plastica Monregalese Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
CA2450625A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
ES2414706T3 (es) 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN100339078C (zh) 2002-12-16 2007-09-26 橘生药品工业株式会社 固体口服剂型药物
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
SI1644336T1 (sl) 2003-06-06 2011-06-30 Fibrogen Inc Heteroarilne spojine, ki vsebujejo duĺ ik in njihova uporaba pri zviĺ anju endogenega eritropoetina
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
AU2004259675A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine CGRP receptor antagonists
US20070042937A1 (en) 2003-08-01 2007-02-22 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
CN1832920A (zh) 2003-08-08 2006-09-13 特兰斯泰克制药公司 芳基和杂芳基化合物,组合物及其使用方法
CA2559630C (en) 2004-03-16 2012-04-17 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
JP2008500834A (ja) 2004-05-28 2008-01-17 ファイブローゲン、インコーポレーテッド Ｈｉｆプロリルヒドロキシラーゼ活性アッセイ
GB2421013B (en) 2004-12-10 2007-07-11 Amcor Flexibles Europe As Packaging with an openable top wall
CN101166745A (zh) 2005-03-02 2008-04-23 菲布罗根有限公司 噻吩并吡啶化合物和其使用方法
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US7928120B2 (en) 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
EP1991269A1 (en) 2006-02-16 2008-11-19 Fibrogen, Inc. Compounds and methods for treatment of stroke
CN101460497A (zh) 2006-04-04 2009-06-17 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007141743A2 (en) 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
EP2370422B1 (en) 2008-11-14 2019-06-05 Fibrogen, Inc. Thiochromene derivatives as hif hydroxylase inhibitors
JP5479949B2 (ja) 2009-04-08 2014-04-23 株式会社東芝 測定装置、測定方法、及び二酸化炭素回収システム
JP2010248106A (ja) 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US8339523B2 (en) 2010-05-18 2012-12-25 Kabushiki Kaisha Toshiba Television apparatus and electronic apparatus
CN101880914B (zh) 2010-05-25 2012-09-12 中国科学院微电子研究所 利用等离子体浸没离子注入制备黑硅的方法
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
CN104024227B (zh) * 2011-07-22 2015-12-02 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
CN104470899B (zh) 2012-03-09 2017-12-26 菲布罗根有限公司 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
IN2015KN00265A (ja) 2012-07-16 2015-06-12 Fibrogen Inc
CN107501177B (zh) 2012-07-16 2018-12-07 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CA2899024C (en) 2013-01-24 2022-01-04 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형

Also Published As

Publication number Publication date
CN114409596A (zh) 2022-04-29
CN107382860A (zh) 2017-11-24
AU2013290438B2 (en) 2017-09-14
HUE057925T2 (hu) 2022-06-28
CN104684897A (zh) 2015-06-03
IL236626B (en) 2020-03-31
CN107382859A (zh) 2017-11-24
KR20150058154A (ko) 2015-05-28
CN115093370A (zh) 2022-09-23
CN103539735A (zh) 2014-01-29
US20140024676A1 (en) 2014-01-23
ES2905898T3 (es) 2022-04-12
WO2014014835A8 (en) 2014-11-20
EP3470397B1 (en) 2021-12-29
IL236626A0 (en) 2015-02-26
HUE041458T2 (hu) 2019-05-28
JP2018009034A (ja) 2018-01-18
US20150322015A1 (en) 2015-11-12
ES2689430T3 (es) 2018-11-14
CN107382859B (zh) 2018-09-14
US9115085B2 (en) 2015-08-25
DK3470397T3 (da) 2022-03-14
RS57795B1 (sr) 2018-12-31
LT2872488T (lt) 2018-10-25
KR102149380B1 (ko) 2020-08-28
JP2015522616A (ja) 2015-08-06
RS63122B1 (sr) 2022-05-31
KR20210130849A (ko) 2021-11-01
FR22C1030I2 (fr) 2024-08-02
US20200115344A1 (en) 2020-04-16
MX2015000504A (es) 2015-07-17
US20140303202A9 (en) 2014-10-09
CN107540607A (zh) 2018-01-05
SG10202111314YA (en) 2021-12-30
AU2013290438A1 (en) 2015-02-19
JP6491093B2 (ja) 2019-03-27
BR112015001101A2 (pt) 2017-06-27
CY1120805T1 (el) 2019-12-11
CN107501177A (zh) 2017-12-22
EP2872488B1 (en) 2018-08-22
US20170190667A1 (en) 2017-07-06
LTPA2022510I1 (ja) 2022-07-25
HK1243409A1 (zh) 2018-07-13
KR20200102556A (ko) 2020-08-31
CN103539735B (zh) 2017-08-04
SI2872488T1 (sl) 2018-11-30
NZ704662A (en) 2017-07-28
US9617218B2 (en) 2017-04-11
KR102318720B1 (ko) 2021-10-28
IN2015KN00262A (ja) 2015-06-12
WO2014014835A2 (en) 2014-01-23
AU2013290438B9 (en) 2018-07-19
DK2872488T3 (en) 2018-10-29
KR20220164068A (ko) 2022-12-12
CY1125155T1 (el) 2023-01-05
LT3470397T (lt) 2022-02-25
CN107501177B (zh) 2018-12-07
MY182428A (en) 2021-01-25
MX355428B (es) 2018-04-18
CN109369524A (zh) 2019-02-22
HRP20220182T1 (hr) 2022-04-29
SG10201700873UA (en) 2017-04-27
EP2872488A2 (en) 2015-05-20
EP3470397A1 (en) 2019-04-17
EP4029854A1 (en) 2022-07-20
WO2014014835A3 (en) 2014-08-21
PT2872488T (pt) 2018-11-22
US20190276408A1 (en) 2019-09-12
PL2872488T3 (pl) 2019-01-31
AU2013290438C1 (en) 2019-01-03
CA2879242C (en) 2023-05-09
PL3470397T3 (pl) 2022-06-20
SI3470397T1 (sl) 2022-07-29
CA2879242A1 (en) 2014-01-23
NO2022024I1 (no) 2022-06-15
US10118897B2 (en) 2018-11-06
HRP20181751T1 (hr) 2018-12-28
PT3470397T (pt) 2022-02-18
SG11201500236SA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
FR22C1030I2 (fr) Formes cristallines d'un inhibiteur de la prolyle hydroxylase
HUS2200030I1 (hu) Prolil hidroxiláz inhibitor kristályos alakjai
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
BR112014003214A2 (pt) polimorfos inibidores de cinase
CO7071137A2 (es) Compuetos inhibidores de beta-lactamasas
CR20120576A (es) Inhibidores de pirazolil quinazolina cinasa
DK2496236T3 (da) Prolylhydroxylasehæmmere
BRPI0910307A2 (pt) inibidores de hiv integrase
BR112012002134A2 (pt) compostos inibidores de apaf-1
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
BR112013009935C8 (pt) compostos
BR112013003753A2 (pt) compostos
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
DK2648516T3 (da) Substituerede pyridinon-pyridinylforbindelser
BRDI7103669S (pt) "configuração aplicada em carrinho de ferramenta"
CO6801726A2 (es) Compuestos
UY33156A (es) Nuevos compuestos tienopirrol
DK2649070T3 (da) Triazolpyridinforbindelser
SMT201600083B (it) Nuove forme e sali di un inibitore di diidropirrolo[1,2-c]imidazolil aldosterone sintasi o aromatasi
BR112013014484A2 (pt) compostos inibidores de metaloenzimas
BR112013018329A2 (pt) ferramenta de perfilagem
ITMI20110184A1 (it) Composti fotosensibilizzanti "metal free"
DK2503946T3 (da) Værktøjsoptager